Kimberly M Thompson Selected Research

Poliovirus Vaccines

1/2024	Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
10/2023	Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
1/2023	Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
11/2022	Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
1/2021	Potential Future Use, Costs, and Value of Poliovirus Vaccines.
1/2020	Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.
1/2017	Poliovirus vaccination during the endgame: insights from integrated modeling.
12/2016	The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.
1/2012	Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.
12/2006	Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kimberly M Thompson Research Topics

Disease

57	Poliomyelitis (Polio) 01/2024 - 12/2006
10	Measles 01/2017 - 07/2012
9	Rubella (German Measles) 01/2017 - 07/2012
8	Infections 10/2023 - 04/2013
3	Paralysis (Palsy) 01/2024 - 06/2023
3	COVID-19 01/2023 - 01/2021
2	Reinfection 01/2016 - 04/2013
2	Vaccine-Preventable Diseases 01/2016 - 06/2010
1	acute flaccid myelitis 01/2024
1	Shoulder Injuries 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Communicable Diseases (Infectious Diseases) 01/2018
1	Mumps 01/2017
1	Congenital Rubella Syndrome (Syndrome, Congenital Rubella) 01/2016
1	Primary Immunodeficiency Diseases 09/2015
1	Drowning 03/2003
1	Whooping Cough (Pertussis) 12/2002

Drug/Important Bio-Agent (IBA)

60	VaccinesIBA 01/2024 - 12/2002
32	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 06/2023 - 12/2006
14	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2024 - 12/2006
10	Poliovirus VaccinesIBA 01/2024 - 12/2006
3	Rubella VaccineIBA 01/2017 - 01/2016
2	Antiviral Agents (Antivirals)IBA 10/2023 - 09/2015
2	Measles VaccineIBA 01/2016 - 01/2016
2	AntibodiesIBA 01/2016 - 01/2016
1	WastewaterIBA 01/2024
1	Hepatitis B e AntigensIBA 01/2017
1	Cholera Vaccines FDA Link 01/2016
1	AntigensIBA 01/2016
1	Vitamin A (Retinol)FDA LinkGeneric 12/2010
1	Hazardous Substances (Hazardous Materials)IBA 12/2006
1	neodymium pyrocatechin disulfonate (NPD)IBA 03/2003

Therapy/Procedure

1	Protective Devices (Safety Device) 03/2003